{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:43:30Z","timestamp":1791474210519,"version":"4.3.4"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T00:00:00Z","timestamp":1510531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Today's doping tests involve longitudinal monitoring of urinary steroids including the testosterone glucuronide and epitestosterone glucuronide ratio (T\/E) in an Athlete Biological Passport (ABP). The aim of this study was to investigate the possible influence of short\u2010term use of codeine on the urinary excretion of androgen metabolites included in the steroidal module of the passport prior to and after the co\u2010administration with testosterone. The study was designed as an open study with the subjects being their own control. Fifteen healthy male volunteers received therapeutic doses of codeine (Kodein Meda) for 6\u2009days. On Day 3, 500\u2009mg or 125\u00a0mg of testosterone enanthate (Testoviron\u00ae\u2010Depot) was administered. Spot urine samples were collected for 17\u2009days, and blood samples were collected at baseline, 3, 6, and 14\u00a0days after codeine intake. The circulatory concentration of total testosterone decreased significantly by 20% after 3\u00a0days' use of codeine (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.0002) and an atypical ABP result was noted in one of the subjects. On the other hand, the concomitant use of codeine and testosterone did not affect the elevated urinary T\/E ratio. In 75% of the individuals, the concentration of urinary morphine (a metabolite of codeine) was above the decision limit for morphine. One of the participants displayed a morphine\/codeine ratio of 1.7 after codeine treatment, indicative of morphine abuse. In conclusion, our study shows that codeine interferes with the endogenous testosterone concentration. As a result, the urinary steroid profile may lead to atypical findings in the doping test.<\/jats:p>","DOI":"10.1002\/dta.2301","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T07:02:35Z","timestamp":1505286155000},"page":"723-730","source":"Crossref","is-referenced-by-count":11,"title":["Codeine influences the serum and urinary profile of endogenous androgens but does not interact with the excretion rate of administered testosterone"],"prefix":"10.1002","volume":"10","author":[{"given":"M.","family":"Lehtihet","sequence":"first","affiliation":[{"name":"Department of Medicine and Molecular Medicine and Surgery Karolinska Institutet at Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"B\u00f6rjesson","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Karolinska University Hospital  Stockholm Sweden"},{"name":"Department of Laboratory Medicine Karolinska Institutet at, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schulze","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institutet at, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rane","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institutet at, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ericsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Karolinska University Hospital  Stockholm Sweden"},{"name":"Department of Laboratory Medicine Karolinska Institutet at, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-2345","authenticated-orcid":false,"given":"L.","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institutet at, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2014-093560"},{"key":"e_1_2_6_3_1","unstructured":"World Anti\u2010Doping Agency.Technical document TD2016EAAS. Endogenous Anabolic Androgenic Steroids \u2010 Measurements and Reporting.https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/wada\u2010td2016eaas\u2010eaas\u2010measurement\u2010and\u2010reporting\u2010en.pdf. 1 January 2017."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0218"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282fad38a"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.2.7958"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2003.10.005"},{"key":"e_1_2_6_8_1","unstructured":"World Anti\u2010Doping Agency.The 2017 Prihibited List.https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/2016\u201009\u201029_\u2010_wada_prohibited_list_2017_eng_final.pdf. 1 January 2017."},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/03602537508993748","article-title":"The metabolism of morphine and heroin in man","volume":"3","author":"Boerner U","year":"1975","journal-title":"Drug Metab Rev"},{"key":"e_1_2_6_10_1","first-page":"73","article-title":"The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)","volume":"26","author":"Coffman BL","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181850df6"},{"key":"e_1_2_6_12_1","first-page":"1","article-title":"Adrenal insufficiency in acute oral opiate therapy","volume":"2014","author":"Policola C","year":"2014","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"e_1_2_6_13_1","first-page":"48","volume-title":"Athletic Training and Sports Medicine","author":"Hedge DD","year":"2006"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2121"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1841"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1300\/J069v21n04_05"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(25)30047-9","article-title":"Plasma testosterone levels in heroin addiction and during methadone maintenance","volume":"192","author":"Mendelson JH","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197504242921703"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200009000-00011"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(92)90229-C"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0026-895X(25)08524-4","article-title":"Divergent regulation of cytochrome P450 enzymes by morphine and pethidine: a neuroendocrine mechanism?","volume":"47","author":"Rane A","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.02.044"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.6.6615"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-595X(86)80021-4"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-8-1-1"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.03.024"},{"key":"e_1_2_6_27_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MED.0000000000000335","article-title":"Androgens and athletic performance of elite female athletes","volume":"24","author":"Bermon S","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2014.00050","article-title":"The impact of genetics and hormonal contraceptives on the steroid profile in female athletes","volume":"5","author":"Schulze JJ","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2013.01.014"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S71285"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1373\/49.8.1381"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2017.1286685"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365513.2014.942694"},{"key":"e_1_2_6_34_1","unstructured":"World Anti\u2010Doping Agency.Technical document TD2017 v2.https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/wada\u2010td2017dl\u2010v2\u2010en_0.pdf. 1 January 2017."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1990.tb03641.x"},{"key":"e_1_2_6_36_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5812\/asjsm.28798","article-title":"Morphine\/codeine ratio, a key in investigating a case of doping","volume":"6","author":"Seif\u2010Barghi T","year":"2015","journal-title":"Asian J Sports Med"},{"key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jat\/25.6.486","article-title":"Concentration ratios of codeine\u2010to\u2010morphine in plasma after a single oral dose (100 mg) of codeine phosphate","volume":"25","author":"Kronstrand R","year":"2001","journal-title":"J Anal Toxicol"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/32.2.178"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500406"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.08.020"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00053-5"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21027"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.2301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T10:16:56Z","timestamp":1760350616000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.2301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,13]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/dta.2301"],"URL":"https:\/\/doi.org\/10.1002\/dta.2301","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,13]]}}}